New hope for tough leukemia? early trial tests AB8939

NCT ID NCT05211570

Recruiting now Disease control Sponsor: AB Science Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called AB8939, given daily through a vein, for people with acute myeloid leukemia that has come back or not responded to standard treatments. About 78 participants will receive AB8939, sometimes with another drug called venetoclax. The main goals are to find a safe dose and see if the drug can shrink or control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AB8939 (a drug given intravenously) and venetoclax (a chemotherapy pill)
What this could lead to: If successful, this could point toward a new treatment option for people with acute myeloid leukemia that has come back or not responded to other therapies.
What could go wrong: This is an early phase 1/2 trial with only 78 participants, so it is too soon to know if AB8939 is safe or effective. The drug may cause serious side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia GATA2 Deficiency myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA, IN RELAPSE MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Clínica Universidad de Navarra
RECRUITING

Pamplona, Spain
General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante)
RECRUITING

Alicante, Spain
Hospital San Pedro de Alcantara
RECRUITING

Cáceres, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, Spain
Hospital Universitario Quirónsalud
RECRUITING

Madrid, Spain
Institut Paoli Calmettes
NOT_YET_RECRUITING

Marseille, France
MD Anderson Cancer Center
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
MD Anderson Cancer Center Madrid
RECRUITING

Madrid, Spain
National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit
RECRUITING

Athens, Greece
Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío)
RECRUITING

Seville, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.